Please login to the form below
China
This page shows the latest China news and features for those working in and with pharma, biotech and healthcare.
BeiGene announces positive phase 3 trial results for liver cancer treatment
BeiGene has already secured approval for the PD-1 inhibitor in China for the treatment of non-small cell lung cancer (NSCLC), classical Hodgkin lymphoma, HCC and PD-L1-high urothelial
Latest news
-
Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
The drug is currently approved in more than 70 markets around the world, including the US, EU Japan and China, to treat adults with non-metastatic castration-resistant prostate cancer (nmCRPC)
-
Sanofi and Innovent Biologics to develop oncology drugs for patients in China
Innovent is a biopharmaceutical company with proven clinical development capabilities and a broad commercial footprint in China. ... our key oncology medicines in selected combinations with sintilimab, but also bolster our overall presence in oncology in
-
Merck KGaA announces launch of start-up collaboration programme in Asia
This is not the first time the company has offered support for emerging start-up companies in China. ... In the past three years, 30 start-ups were enrolled in the Merck China Accelerator programme.
-
BeiGene and InnoRNA join to research novel mRNA therapies
The company has already secured approval for the PD-1 inhibitor in China for the treatment of non-small cell lung cancer (NSCLC), classical Hodgkin lymphoma, liver cancer hepatocellular carcinoma (HCC)
-
Novartis announces positive phase 3 trial results for advanced oesophageal cancer
NSCLC. BeiGene, tislelizumab’s original developer, has already secured approval for the PD-1 inhibitor in China for the treatment of non-small cell lung cancer (NSCLC), classical Hodgkin lymphoma, liver
More from news
Approximately 113 fully matching, plus 623 partially matching documents found.
Latest Intelligence
-
A new era for UK-Japanese scientific research relations
Japan has held the mantle of Asia’s scientific leader for decades and while other countries, notably South Korea and China, are investing heavily in infrastructure, human resources and R&D,
-
The search for effective drug treatments for COVID-19
Lastly, the two randomised, double-blind, placebo controlled clinical trials were conducted at multiple sites in Hubei province, China, where the infection was first described. ... They were coordinated by the China-Japan Friendship Hospital in Beijing.
-
Has AI been the key to tackling the COVID-19 pandemic?
Indeed, a World Health Organization report released in February 2020 highlighted the important role that artificial intelligence and big data played in China’s initial response to the outbreak. ... In an effort to quickly curb the spread of the disease,
-
Gut instincts lead Takeda to GI pipeline success
Our motivation is clear. IBD has also been on the rise even in places where historically it didn’t have much of an impact, such as China, Japan, South-East Asia
-
Things are going to be different
China has a near 600% increase, Korea 165%, Italy 286% and Spain 145%.
More from intelligence
Approximately 18 fully matching, plus 124 partially matching documents found.
Latest appointments
-
Ashfield Advisory adds Mary-Kate McGarry and Emer Jameson to senior leadership team
Prior to joining Ashfield Advisory, Jameson (pictured right) had a varied career in international HR and commercial roles, including time spent working at Saongroup in China and as global chief people
-
Porterhouse announces members of medical advisory group
In addition to her education experience, Daoud has undertaken volunteering work in China and Peru, and completed her medical elective in Nepal, where she worked in a primary healthcare centre in
-
New hires at Bayer, Eisai and Accord Healthcare
In that role, Chaturvedi oversaw the end-to-end quality assurance for a large portfolio of clinical trials across all therapeutic areas in the Asia-Pacific region, including China.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
inflammation test for managing asthma, across key markets such as the United States, China, and Japan, as well as the rest of the world.
-
BMS appoints new commercial leader, Davies joins Eisai and more
Her international experience will support our operational expansion in the UK and across Europe, China and the US.”.
More from appointments
Approximately 2 fully matching, plus 38 partially matching documents found.
Latest from PMHub
-
Infographic: Therapy Watch Lupus
Therapy Watch Lupus patient data is collected from a panel of 600 physicians across the main 5 EU markets, China, Japan, and the US.
-
Medscape Education Global
Clarivate, Taking the Pulse Europe 2021. Medscape reaches over 5 million physicians worldwide, in multiple languages with strategic partnerships in Europe, China and Japan to maximize reach.
-
11 London are delighted to announce our collaboration with health psychologist, Prof. Anne Manyande
projects in China.
-
M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia
Presence outside of Japan includes the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its
-
Lesson Learned from the Pandemic
Tom Hsu, VP of Specialty Medicine at Bayer Canada, talks about how he got to where he is today and his experience working for Bayer in China and how that compares
More from PMHub
Approximately 11 fully matching, plus 79 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
